Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAULT: Aflibercept for Polypoidal Choroidal Vasculopathy
NCT01950741Phase 4Completed
- Sponsor
- Pusan National University Hospital
- Start
- Sep 2013
- Primary completion
- May 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in polypoidal choroidal vasculopathy (PCV), sponsored by Pusan National University Hospital. Primary endpoint: Percentage of Patients Lose Visual Acuity Less Than 15 Letters at 12 months. Started Sep 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT01950741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01950741.